HMGA2 TARGETED THERAPY OF RETINOBLASTOMA TUMORS
- Detailed Technology Description
- None
- Others
-
- *Abstract
-
University of MissouriOffice of Technology Management & Industry RelationsNon-Confidential Abstract of InventionUM Disclosure No. 17UMC004Targeted Retinoblastoma TherapyINNOVATIONResearchers at the University of Missouri have developed two new aptamer platform technologies that can target and bind HMGA2 using specially designed targeted nanoparticles. HMGA2 has been shown to be upregulated in a large number of cancers, particularly retinoblastoma. These new platforms achieve intended therapeutic effects by penetrating the cellular bilayer.BACKGROUNDHMGA2 is an architectural transcription factor, a large protein that is responsible for the upregulation of oncogenic and tumor proliferative mechanisms. The protein HMGA2 has been highly associated with retinoblastoma, as well as other cancers. Controlling HMGA2 levels could lead to first effective treatment methods of retinoblastoma.Retinoblastoma is a life threatening cancer that occurs in the eye and can spread to other parts of the body. Almost exclusively found in young children, current retinoblastoma treatments include photocoagulation, cryotherapy, chemotherapy, radiation therapy, or enucleation. To date, there is no minimally invasive treatments for retinoblastoma.APPLICATIONS• Retinoblastoma• Cancer prevention• Targeted cancer treatmentADVANTAGES• Minimally invasive • Minimal risk• Potentially less drug rejection• Cost-effective productionPATENT STATUSPatent PendingLICENSING POTENTIAL• University seeks licensee with the potential to commercializeINVENTOR(S)• Raghuraman Kannan• Anandhi Upendran• Ajit Zambre• Subramanian Krishnakumar CONTACT INFO Office of Technology Management & Industry Relations Brian Buntaine, MS, MBA Senior Licensing & Business Development Associate Email: buntaineb@missouri.edu Phone: 573-882-0470
- *Principal Investigator
-
Name: Raghuraman Kannan
Department:
Name: Anandhi Upendran, Director of Biomed Innovation
Department:
Name: Ajit Zambre, Post Doctoral Fellow
Department:
Name: Subramanian Krishnakumar, Head, Ocular Pathology
Department:
- Country/Region
- USA
For more information, please click Here
